When Boring is Excellent: The Ups and Downs of Cancer Follow-Up Appointments

Article

Waiting to hear if one’s blood is showing any signs of the monster’s return has never been easy.

“Your blood work looks boring.” Many people would be stunned to hear this report from their doctor. For a cancer survivor of eight years and a frequent flyer in the oncology office, it was a welcome relief.

Waiting to hear if one’s blood is showing any signs of the monster’s return has never been easy. The relief that came from hearing that, in the oncology world, “boring” means “excellent,” was, however, short lived as I left the appointment with yet another follow-up appointment and another PET scan on the books.

Early in recovery, the appointments for blood work and scans seemed to make perfect sense. However, I would be lying if I said that I wasn’t hoping to hear at the end of every follow-up visit, “No need to come back, our work here is done.”

I’m told that the reason for these continued checks for cancer’s return is due to my young age, despite the fact 58 no longer feels young, and of course the all-important, “If we catch it early we have a better chance of treatment.” Still, I can’t help but wonder if there is ever a right time to withdraw oneself from the not-so-merry-go-round of tests, waiting, results, tests and waiting.

I think it’s fair to ask when we cancer survivors can finally move on to the other joys of aging like arthritic joints, gastrointestinal issues and memory loss without having to wonder is these are symptoms of a cancerous tumor growing in the shadows. Is it fool-hearty or heart-strong to finally put oncology behind and live with the inevitable aches and pains of life and trust that years of a cancer-free thumbs up is permission to move on?

I tell myself that the reason for not wanting any more PET scans is not my anxiety that it will reveal cancer’s return, but that I hate the taste of the barium swallow—my request for Pina Colada flavor is always met with apologies for only having mixed berry—and the idea of having tracer radiation injected into my body. The fact is that I’ve had this same inner dialogue after every appointment since hitting what I once thought was the finish line of the five-year mark. I’ve realized that telling myself that I can choose whenever I want to stop the follow-up visits has more to do with calming down my anxious mind than a practical decision about what is best for my health.

Despite my recent decision to give thumbs down to any more oncology visits, I’m certain that sometime within the next two months I will be asking for Pina Colada flavored barium, waiting while my body is filled with radioactive sugar and once again telling myself that this is the last PET scan I will endure. This is my cancer ritual and it has a strange purpose in my strange life—a life I continue to enjoy as a result of having caught my cancer early enough.

Related Videos
For patients with cancer, the ongoing chemotherapy shortage may cause some anxiety as they wonder how they will receive their drugs. However, measuring drugs “down to the minutiae of the milligrams” helped patients receive the drugs they needed, said Alison Tray. Tray is an advanced oncology certified nurse practitioner and current vice president of ambulatory operations at Rutgers Cancer Institute in New Jersey.  If patients are concerned about getting their cancer drugs, Tray noted that having “an open conversation” between patients and providers is key.  “As a provider and a nurse myself, having that conversation, that reassurance and sharing the information is a two-way conversation,” she said. “So just knowing that we're taking care of you, we're going to make sure that you receive the care that you need is the key takeaway.” In June 2023, many patients were unable to receive certain chemotherapy drugs, such as carboplatin and cisplatin because of an ongoing shortage. By October 2023, experts saw an improvement, although the “ongoing crisis” remained.  READ MORE: Patients With Lung Cancer Face Unmet Needs During Drug Shortages “We’re really proud of the work that we could do and achieve that through a critical drug shortage,” Tray said. “None of our patients missed a dose of chemotherapy and we were able to provide that for them.” Tray sat down with CURE® during the 49th Annual Oncology Nursing Society Annual Congress to discuss the ongoing chemo shortage and how patients and care teams approached these challenges. Transcript: Particularly at Hartford HealthCare, when we established this infrastructure, our goal was to make sure that every patient would get the treatment that they need and require, utilizing the data that we have from ASCO guidelines to ensure that we're getting the optimal high-quality standard of care in a timely fashion that we didn't have to delay therapies. So, we were able to do that by going down to the minutiae of the milligrams on hand, particularly when we had a lot of critical drug shortages. So it was really creating that process to really ensure that every patient would get the treatment that they needed. For more news on cancer updates, research and education, don’t forget to subscribe to CURE®’s newsletters here.
Yuliya P.L Linhares, MD, an expert on CLL
Yuliya P.L Linhares, MD, and Josie Montegaard, MSN, AGPCNP-BC, experts on CLL
Image of a man with a beard.
Image of a man with gray facial hair and a navy blue suit with a light orange tie.
Image of a woman with black hair.
Related Content